Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ANPEP | P15144 | 2/20 | 0.33 |
| ▸ | LAP3 | P28838 | 2/20 | 0.33 |
| ▸ | LPL | P06858 | 1/20 | 0.32 |
| ▸ | LIPG | Q9Y5X9 | 1/20 | 0.32 |
| ▸ | APLNR | P35414 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17130198 | 0.81 | — | — | |
| SCHEMBL12018785 | 0.75 | LPL (0.34) | ANPEPLAP3LPLLIPG | |
| SCHEMBL19850883 | 0.74 | — | — | |
| SCHEMBL24215486 | 0.73 | — | — | |
| SCHEMBL21567950 | 0.72 | — | — | |
| SCHEMBL21431208 | 0.72 | — | — | |
| SCHEMBL18387576 | 0.71 | LPL (0.37) | LPLLIPG | |
| SCHEMBL3197440 | 0.71 | ANPEP (0.32) | ANPEPLAP3APLNR | |
| SCHEMBL13857694 | 0.71 | ANPEP (0.32) | ANPEPLAP3APLNR | |
| SCHEMBL12991901 | 0.71 | ANPEP (0.38) | ANPEPLAP3APLNR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 233 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-112280272-A | High-molecular packaging material and preparation method thereof | 程朝刚 | 2021-01-29 | — | — | CN | claimed |
| EP-3727380-B1 | PURINE INHIBITORS OF HUMAN PHOSPHATIDYLINOSITOL 3-KINASE DELTA | MERCK SHARP & DOHME LLC (US) | 2025-09-24 | — | — | EP | disclosed |
| WO-2025106383-A1 | PYRROLIDINYL DERIVATIVES USEFUL AS HCN1/HCN 2 MODULATORS | MERCK SHARP & DOHME LLC (US) | 2025-05-22 | — | — | WO | disclosed |
| WO-2025080784-A1 | EGFR INHIBITORS | BLUEPRINT MEDICINES CORPORATION (US) | 2025-04-17 | — | — | WO | disclosed |
| WO-2024163962-A1 | 3-((1,1-DIOXIDO-2,3,4,5-TETRAHYDROBENZO[F][1,2,5]THIADIAZEPIN-8-YL)OXY)-2-FLUOROACRYLIC ACID DERIVATIVES AS SODIUM TAUROCHOLATE CO-TRANSPORTING POLYPEPTIDE (NTCP) INHIBITORS FOR THE TREATMENT OF CHOLESTASIS | Hemoshear Therapeutics, Inc. (US) | 2024-08-08 | — | — | WO | disclosed |
| CN-115745971-B | PARP7 inhibitor and application thereof | 北京华森英诺生物科技有限公司 | 2024-07-30 | — | — | CN | disclosed |
| US-12043636-B2 | Method for producing triarylorganoborates | COVESTRO INTELLECTUAL PROPERTY GMBH & CO. KG (DE) | 2024-07-23 | — | — | US | disclosed |
| US-12043600-B2 | Microbiocidal compounds | SYNGENTA CROP PROTECTION AG (CH) | 2024-07-23 | — | — | US | disclosed |
| US-20240239752-A1 | BICYCLIC HETEROAROMATIC INHIBITORS OF KLK5 | WILMINGTON TRUST, NATIONAL ASSOCIATION | 2024-07-18 | — | — | US | disclosed |
| EP-4393920-A1 | AROMATIC RING-CONTAINING BIOLOGICAL ANTAGONIST, AND PREPARATION METHOD THEREFOR AND USE THEREOF | Shanghai Hansoh Biomedical Co., Ltd. (CN) | 2024-07-03 | — | — | EP | disclosed |
| US-7528157-B2 | EP4 receptor antagonists | ASTERAND UK LIMITED (GB) | 2009-05-05 | — | — | US | disclosed |
| US-20090082403-A1 | PYRIDINE DERIVATIVES SUBSTITUTED BY HETEROCYCLIC RING AND PHOSPHONOAMINO GROUP, AND ANTI-FUNGAL AGENT CONTAINING SAME | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2009-03-26 | — | — | US | disclosed |
| US-7507754-B2 | EP4 receptor antagonists | ASTERAND UK LIMITED (GB) | 2009-03-24 | — | — | US | disclosed |
| US-20080261318-A1 | Signalling Compounds For Use In Methods Of Detecting Hydrogen Peroxide | LUMIGEN, INC. (US) | 2008-10-23 | — | — | US | disclosed |
| US-20080039502-A1 | EP4 receptor antagonists | ASTERAND UK LIMITED (GB) | 2008-02-14 | — | — | US | disclosed |
| US-20070129314-A1 | Treating Type II diabetes comprising coadministering metformin and an inhibitor of dipeptidylpeptidase IV, especially a peptidomimetic containing a pyrrolidine ring in an amount insufficient to suppress the immune system | TRUSTEES OF TUFTS COLLEGE (US) | 2007-06-07 | — | — | US | disclosed |
| US-20070123575-A1 | EP4 RECEPTOR ANTAGONISTS | ASTERAND UK ACQUISITION LIMITED (GB) | 2007-05-31 | — | — | US | disclosed |
| US-20070105904-A1 | 3-(3-(4-(pyridin-2-yloxymethyl)-benzyl)-isoxazol-5-yl)-pyridin-2-ylamine; inhibiting fungal GPI biosynthesis thereby inhibiting expression of cell wall proteins and blocking cell wall assembly while preventing the fungus from attaching to cells | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2007-05-10 | — | — | US | disclosed |
| US-7196089-B2 | EP4 receptor antagonists | ASTERAND UK LIMITED (GB) | 2007-03-27 | — | — | US | disclosed |
| US-7189877-B2 | Arylamine derivatives having fluorene skeleton, synthetic intermediates thereof, processes of producing those, and organic electrolumivescene devices | TOSCH CORPORATION (JP) | 2007-03-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12043600-B2 | Microbiocidal compounds | MPO, MSR1, PRF1 | ANPEP 1136/4885LAP3 1229/4885LPL 566/4885 |
| US-20090082403-A1 | PYRIDINE DERIVATIVES SUBSTITUTED BY HETEROCYCLIC RING AND PHOSPHONOAMINO GROUP, AND ANTI-FUNGAL AGENT CONTAINING SAME | ERG28, H1-2, H1-3 | ANPEP 1822/4885LAP3 2790/4885LPL 4846/4885 |
| US-20070129314-A1 | Treating Type II diabetes comprising coadministering metformin and an inhibitor of dipeptidylpeptidase IV, especially a peptidomimetic containing a pyrrolidine ring in an amount insufficient to suppress the immune system | DPP4, DPP7, LPL | ANPEP 34/4885LAP3 311/4885LPL 3/4885 |
| US-20240239752-A1 | BICYCLIC HETEROAROMATIC INHIBITORS OF KLK5 | KLK5, KLK1, KLKB1 | ANPEP 766/4885LAP3 203/4885LPL 640/4885 |
| US-12043636-B2 | Method for producing triarylorganoborates | KMO, COASY, CYP3A4 | ANPEP 3130/4885LAP3 3398/4885LPL 1072/4885 |
| US-20070105904-A1 | 3-(3-(4-(pyridin-2-yloxymethyl)-benzyl)-isoxazol-5-yl)-pyridin-2-ylamine; inhibiting fungal GPI biosynthesis thereby inhibiting expression of cell wall proteins and blocking cell wall assembly while preventing the fungus from attaching to cells | GPI, ERG28, MAN2A1 | ANPEP 920/4885LAP3 2297/4885LPL 4155/4885 |
| US-20070123575-A1 | EP4 RECEPTOR ANTAGONISTS | PTGER4, NR4A1, PTGER1 | ANPEP 2051/4885LAP3 3338/4885LPL 4557/4885 |
| US-20080039502-A1 | EP4 receptor antagonists | PTGER4, NR4A1, PTGER1 | ANPEP 2101/4885LAP3 3347/4885LPL 4597/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.